secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-04-14T23:59:59+00:00
Accession:  0001193125-22-105004
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics prioritizes MGTA-117, cuts workforce 14%, extends cash runway into Q2 2024
--------------------------------------------------------------------------------

- MGTA-117 Phase 1/2 trial shows encouraging early data: well-tolerated with no significant adverse events, early pharmacodynamic signals.
- Company reduces workforce by 14% and extends cash runway into Q2 2024 through spending prioritization.
- Magenta to disclose summary of clinical observations from initial MGTA-117 patients in Q1 2022 earnings release in early May.
- De-prioritizing other portfolio investments, pausing MGTA-145 dosing optimization trial in healthy subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522105004/0001193125-22-105004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522105004/d343288d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-105004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer